Mepolizumab

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

IL-5 antibody

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Mepolizumab is a humanized monoclonal antibody that binds to the cytokine interleukin-5. IL-5 plays an important role in the development, activation, differentiation and survival of eosinophils. The IL-5 antibody reduces eosinophilic granulocytes in the blood and lowers the frequency of disease exacerbations induced by eosinophilic granulocytes.

Field of application/useThis section has been translated automatically.

Mepolizumab in eosinophilic asthma: Mepolizumab is administered for the treatment of "eosinophilic asthma". About 40% of all patients with COPD have eosinophilia. The exact causes are not known.

The IL-5 antibody is used in combination with other drugs in patients whose asthma is severe and is not adequately controlled by prior treatment. In several randomised studies, the IL-5 antibody has been shown to be able to reduce the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD) with eosinophilic phenotype. The dosage was 100mg s.c. every 4 weeks.

Mepolizumab in eosinophilic granulomatosis with polyangiitis: In a randomized, multicenter, double-blind phase III study, mepolizumab was used in eosinophilic granulomatosis with polyangiitis over a period of 52 weeks (dose 300mg s.c. every 4 weeks). Under this therapy, there was a significant reduction in disease activity (reduction in recurrence rate, reduction in glucocorticoid consumption).

Mepolizumab in hypereosinophilic dermatitis: In addition to normalization of eosinophilic leukocytes and a decrease in the concentration of IL-5, TARC, ECP and eotaxin in the blood, the preparation leads to a significant reduction of itching and to an improvement of the skin symptoms of hypereosinophilic dermatitis. Furthermore, a glucocorticoid-saving effect can be expected. The preparation has been granted orphan drug status in Europe and the USA.

Undesirable effectsThis section has been translated automatically.

The most common possible adverse effects include headaches, injection site reactions, back pain and fatigue. In detail:

Infections and parasitic diseases

  • Common: lower respiratory tract infection, urinary tract infection, pharyngitis

Diseases of the immune system Hypersensitivity reactions

  • Rare: anaphylactic reactions like urticaria, angioedema, bronchospasm, hypotension. These reactions generally occur within hours of administration, but in some cases are delayed (i.e. typically within a few days). These reactions may also occur for the first time after long-term use

Diseases of the nervous system:

  • Very common: headache

Diseases of the respiratory tract, chest and mediastinum

  • Common: Nasal congestion

diseases of the gastrointestinal tract

  • Frequently: Pain in the upper abdomen

Diseases of the skin and subcutaneous cell tissue

  • Common: eczematous reactions

Skeletal muscle, connective tissue and bone diseases

  • Frequent: Back pain

General illnesses and complaints at the place of administration

  • Frequent: fever and uncharkateristic reactions at the injection site

PreparationsThis section has been translated automatically.

Nucala®

LiteratureThis section has been translated automatically.

  1. Bel EH et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371: 1189-1197.
  2. Wechsler ME et al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921-1932.

Authors

Last updated on: 29.10.2020